Journal List > J Korean Surg Soc > v.79(2) > 1011218

TOOLS
Jung, Youn, Kim, Kim, Hwang, and Lee: Correlation between the Expression Reduction of Insulin-like Growth Factor Binding Protein (IGFBP)-3 and PTEN and the Clinicopathological Parameters in Breast Cancer
Original Article
Journal of the Korean Surgical Society

Journal of the Korean Surgical Society 2010; 79(2): 79-85.

Published online: 2 August 2010

DOI: https://doi.org/10.4174/jkss.2010.79.2.79

Correlation between the Expression Reduction of Insulin-like Growth Factor Binding Protein (IGFBP)-3 and PTEN and the Clinicopathological Parameters in Breast Cancer

Sung Hoo Jung, M.D.1, Hyun Jo Youn, M.D.1, Min Sun Kim, M.D.2, 3, Sun-Young Kim, Ph.D.2, 3, Pyoung Han Hwang, M.D.2, 3, Dae-Youl Lee, M.D.2, 3

1Department of Surgery, Chonbuk National University Medical School, Jeonju, Korea.

2Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Korea.

3Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea.

Corresponding author (leedy@jbnu.ac.kr)

Received 21 January 2010       Accepted 23 April 2010

Copyright © 2010 The Korean Surgical Society

Abstract

Purpose

Insulin-like growth factor binding protein (IGFBP-3) and phosphatase and tensin homolog (PTEN) are tumor-suppressor genes that may be involved in breast tumorigenesis. However, the roles of these genes in the regulation of breast cancer growth or progress are unclear. In this study, we aimed to find any correlation between the reduction of IGFBP-3 or PTEN protein expression in cancer tissues and the clinicopathological parameters in breast cancer.

Methods

We collected both cancer and adjacent normal tissues from 46 breast cancer patients (from January 1 to December 31, 2006), and checked the IGFBP-3 and PTEN protein levels in cancer and adjacent normal tissues using Western immunoblot. We evaluated the correlation of reduction status of IGFBP-3 and PTEN protein expression with variable clinicopathological parameters.

Results

The frequency of IGFBP-3 and PTEN protein reduction in cancer tissue, compared to adjacent normal tissue, was 63.0% and 34.8%, respectively. And in 87.5% of patients, who showed significant PTEN reduction, IGFBP-3 protein expression was reduced in cancer tissues. In contrast, IGFBP-3 protein reduced in only 50% of patients who didn't show PTEN reduction. However, we did not find any significant correlation between reduction of IGFBP-3 or PTEN expression in cancer tissue and variable clinicopathological parameters.

Conclusion

The IGFBP-3 and PTEN genes were expressed in all breast cancer tissues. Nonetheless, we did not find any significant relationship between reduction of IGFBP-3 or PTEN expression and the clinicopathological parameters in this study. Therefore, further studies are needed to document the roles of IGFBP-3 and PTEN genes in breast cancer growth or progress.

Keywords: Breast cancer, IGFBP-3, PTEN, Clinicopathological parameters

Figures and Tables

Fig. 1
Expression of insulin-like growth factor binding protein (IGFBP)-3 in normal and cancer tissues in human breast cancer. Total protein from normal (N) and cancer (C) tissues from 4 individual breast cancer patients (P1 to P4) were isolated, and subjected to Western immunoblot, as described in the Methods section.
jkss-79-79-g001
Fig. 2
Expression of phosphatase and tensin homolog (PTEN) protein in normal and cancer tissues in human breast cancer. Total protein from normal (N) and cancer (C) tissues from 4 individual breast cancer patients (P1 to P4) were isolated, and subjected to Western immunoblot.
jkss-79-79-g002
Table 1
The relationship of IGFBP-3 and PTEN protein expression reduction in breast cancer with clinicopathological characteristics
jkss-79-79-i001

*IGFBP = insulin-like growth factor binding protein; †PTEN = phosphatase and tensin homolog. ‡*>20% reduction of IGFBP-3 or PTEN protein expression in cancer tissues compared to those of normal tissues. §LM = lymph nodes; ∥ER = estrogen receptor; PR = progesterone receptor.

Table 2
Relation of PTEN reduction with IGFBP-3 reduction in breast cancer
jkss-79-79-i002

*IGFBP = insulin-like growth factor binding protein; †PTEN = phosphatase and tensin homolog.

References

1. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the National Cancer Incidence Database. Cancer Res Treat. 2005. 37:325–331.
2. Andersen TI. Genetic heterogeneity in breast cancer susceptibility. Acta Oncol. 1996. 35:407–410.
3. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989. 3:509–517.
4. Dhar K, Banerjee S, Dhar G, Sengupta K, Banerjee SK. Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells. Cancer Res. 2007. 67:1520–1526.
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995. 16:3–34.
6. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem. 1993. 268:14964–14971.
7. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat. 2002. 74:65–76.
8. Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI, et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg. 2003. 73:905–908.
9. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996. 88:601–606.
10. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998. 351:1393–1396.
11. Shin A, Ren Z, Shu XO, Cai Q, Gao YT, Zheng W. Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat. 2007. 105:55–61.
12. Mu L, Katsaros D, Wiley A, Lu L, de la Longrais IA, Smith S, et al. Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res Treat. 2009. 115:151–162.
13. Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007. 357:154–162.
14. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997. 57:5221–5225.
15. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA. 1998. 95:13513–13518.
16. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology. 2005. 68:398–404.
17. Yi HK, Kim SY, Hwang PH, Kim CY, Yang DH, Oh Y, et al. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochem Biophys Res Commun. 2005. 330:760–767.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991. 19:403–410.
19. Perks CM, Holly JM. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia. 2008. 13:455–469.
20. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res. 1993. 53:5193–5198.
21. Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, et al. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer. 1995. 62:266–270.
22. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. 363:1346–1353.
23. Ren Z, Shin A, Cai Q, Shu XO, Gao YT, Zheng W. IGFBP3 mRNA expression in benign and malignant breast tumors. Breast Cancer Res. 2007. 9:R2.
24. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV, et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997. 3:103–109.
25. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000. 92:924–930.
26. Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002. 33:405–409.
27. Lee JS, Kim HS, Kim YB, Lee MC, Park CS, Min KW. Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast. Appl Immunohistochem Mol Morphol. 2004. 12:205–210.
28. Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2006. 19:238–245.
TOOLS
Similar articles